Unmet expectations

Now that the Scheme booklet is on the virtual bookstands it is worth perusing the first few lines.

The Independent Expert has concluded that the Scheme is fair and reasonable and is in the best interests of Cellestis Shareholders

As a shareholder I had expected the Independent Expert to understand the subtleties of the product

Take-up of novel diagnostic products – the relatively slow take-up rates of interferon gamma release assays. QuantiFERON-TB Gold In-Tube has a market share in the region of 5% despite the QuantiFERON technology being available in the market for more than seven years.

QuantiFERON-TB Gold In-Tube has not been approved for use for seven years and Deloittes know this but have made no distinction between QFT-TB, QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube

Thankfully most shareholders are not as silly as others take them for.

.